AR105102A1 - Derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen - Google Patents

Derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen

Info

Publication number
AR105102A1
AR105102A1 ARP160101880A ARP160101880A AR105102A1 AR 105102 A1 AR105102 A1 AR 105102A1 AR P160101880 A ARP160101880 A AR P160101880A AR P160101880 A ARP160101880 A AR P160101880A AR 105102 A1 AR105102 A1 AR 105102A1
Authority
AR
Argentina
Prior art keywords
group
alkyl
branched
linear
ring
Prior art date
Application number
ARP160101880A
Other languages
English (en)
Spanish (es)
Inventor
Proszenyk Gnes
Ondi Levente
Sipos Szabolcs
Brooke Murray James
Edward Paul Davidson James
chen I
Jen - Geneste Olivier
Chanrion Maa
Kotschy Andrs
Szlvik Zoltn
Cskei Mrton
Blint Balzs
Original Assignee
Les Laboratoires Servier (Société Anonyme)
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier (Société Anonyme), Vernalis R&D Ltd filed Critical Les Laboratoires Servier (Société Anonyme)
Publication of AR105102A1 publication Critical patent/AR105102A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ARP160101880A 2015-06-23 2016-06-23 Derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen AR105102A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1555750A FR3037959B1 (fr) 2015-06-23 2015-06-23 Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
AR105102A1 true AR105102A1 (es) 2017-09-06

Family

ID=54356456

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101880A AR105102A1 (es) 2015-06-23 2016-06-23 Derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen

Country Status (42)

Country Link
US (2) US10323041B2 (cg-RX-API-DMAC10.html)
EP (1) EP3313817B1 (cg-RX-API-DMAC10.html)
JP (1) JP6741699B2 (cg-RX-API-DMAC10.html)
KR (1) KR102782071B1 (cg-RX-API-DMAC10.html)
CN (1) CN108137497B (cg-RX-API-DMAC10.html)
AR (1) AR105102A1 (cg-RX-API-DMAC10.html)
AU (1) AU2016282828B2 (cg-RX-API-DMAC10.html)
CA (1) CA2990084C (cg-RX-API-DMAC10.html)
CL (1) CL2017003205A1 (cg-RX-API-DMAC10.html)
CO (1) CO2017012832A2 (cg-RX-API-DMAC10.html)
CR (1) CR20170575A (cg-RX-API-DMAC10.html)
CU (1) CU24466B1 (cg-RX-API-DMAC10.html)
CY (1) CY1123645T1 (cg-RX-API-DMAC10.html)
DK (1) DK3313817T3 (cg-RX-API-DMAC10.html)
EA (1) EA033566B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP17083003A (cg-RX-API-DMAC10.html)
ES (1) ES2831749T3 (cg-RX-API-DMAC10.html)
FR (1) FR3037959B1 (cg-RX-API-DMAC10.html)
GE (2) GEP20207056B (cg-RX-API-DMAC10.html)
HK (1) HK1254656A1 (cg-RX-API-DMAC10.html)
HR (1) HRP20201782T1 (cg-RX-API-DMAC10.html)
HU (1) HUE051877T2 (cg-RX-API-DMAC10.html)
IL (1) IL256375B (cg-RX-API-DMAC10.html)
JO (1) JO3674B1 (cg-RX-API-DMAC10.html)
LT (1) LT3313817T (cg-RX-API-DMAC10.html)
MA (1) MA42230B1 (cg-RX-API-DMAC10.html)
MD (1) MD3313817T2 (cg-RX-API-DMAC10.html)
MX (1) MX381707B (cg-RX-API-DMAC10.html)
PE (1) PE20181491A1 (cg-RX-API-DMAC10.html)
PH (1) PH12017502315B1 (cg-RX-API-DMAC10.html)
PL (1) PL3313817T3 (cg-RX-API-DMAC10.html)
PT (1) PT3313817T (cg-RX-API-DMAC10.html)
RS (1) RS61179B1 (cg-RX-API-DMAC10.html)
RU (1) RU2760554C1 (cg-RX-API-DMAC10.html)
SI (1) SI3313817T1 (cg-RX-API-DMAC10.html)
SV (1) SV2017005589A (cg-RX-API-DMAC10.html)
TN (1) TN2017000524A1 (cg-RX-API-DMAC10.html)
TW (1) TW201712006A (cg-RX-API-DMAC10.html)
UA (1) UA122498C2 (cg-RX-API-DMAC10.html)
UY (1) UY36734A (cg-RX-API-DMAC10.html)
WO (1) WO2016207217A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201708562B (cg-RX-API-DMAC10.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
CN121974842A (zh) 2016-05-10 2026-05-05 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
WO2018015526A1 (en) 2016-07-22 2018-01-25 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof
MX385115B (es) * 2017-01-06 2025-03-14 Servier Lab Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta.
UY37560A (es) 2017-01-06 2018-07-31 Servier Lab Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
EP4717317A3 (en) 2017-06-20 2026-06-03 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
IL271475B2 (en) 2017-06-22 2023-09-01 Servier Lab Combination of mcl-1 inhibitor and standard medical treatment for hematological cancer, uses and pharmaceutical preparations
AU2018317828A1 (en) * 2017-08-15 2020-04-02 AbbVie Deutschland GmbH & Co. KG Macrocyclic MCL-1 inhibitors and methods of use
CR20200124A (es) 2017-08-15 2020-09-28 Abbvie Inc Inhibidores macrocíclicos de mcl-1 y métodos de uso
CN111372936B (zh) * 2017-11-23 2022-12-02 北京赛林泰医药技术有限公司 Mcl-1选择性抑制剂及其制备和用途
DK3796975T3 (da) 2018-05-22 2023-12-04 Orsobio Inc Sulfonylaminobenzamidderivater
TWI748194B (zh) * 2018-06-28 2021-12-01 德商菲尼克斯 Ｆｘｒ有限責任公司 含有雙環核心部分之新穎lxr調節劑
AR116635A1 (es) 2018-10-15 2021-05-26 Servier Lab Proceso para la síntesis de derivados de piperazinil-etoxi-bromofenilo y su aplicación en la producción de compuestos que los contienen
TWI849001B (zh) 2018-11-14 2024-07-21 法商施維雅藥廠 Mcl-1抑制劑及米哚妥林(midostaurin)之組合，其用途及醫藥組合物
KR101973074B1 (ko) * 2018-11-30 2019-04-26 주식회사 티움바이오 퓨로피리미딘 화합물의 염 및 결정형, 및 이를 포함하는 약학적 조성물
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN BREAKDOWN
AU2020279979A1 (en) 2019-05-20 2021-11-25 Les Laboratoires Servier Mcl-1 inhibitor antibody-drug conjugates and methods of use
WO2020254299A1 (en) 2019-06-17 2020-12-24 Les Laboratoires Servier Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof
WO2021067827A1 (en) * 2019-10-03 2021-04-08 California Institute Of Technology Mcl1 inhibitors and uses thereof
US12522606B2 (en) * 2020-01-09 2026-01-13 University Of Washington Modified pyrrolo- and pyrazolo-pyrimidines for prostate cancer therapy
JP2023553808A (ja) 2020-11-24 2023-12-26 ノバルティス アーゲー Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法
WO2022216946A1 (en) * 2021-04-07 2022-10-13 California Institute Of Technology Mcl1 inhibitors and uses thereof
TWI861509B (zh) 2021-06-11 2024-11-11 美商基利科學股份有限公司 Mcl-1抑制劑與抗體藥物接合物之組合
JP7900421B2 (ja) 2021-06-11 2026-08-04 ギリアード サイエンシーズ， インコーポレイテッド Ｍｃｌ－１阻害剤と抗がん剤との組み合わせ
IL317101A (en) 2022-05-20 2025-01-01 Novartis Ag Antibody-drug conjugates of anticancer compounds and methods of using them
AR134424A1 (es) 2023-11-22 2026-01-14 Novartis Ag Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos
UY40985A (es) 2023-11-22 2025-06-30 Servier Lab Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL188959B1 (pl) 1995-07-06 2005-05-31 Novartis Ag Pirolopirymidyny i sposoby ich wytwarzania
EP1922321A1 (en) * 2005-08-09 2008-05-21 Eirx Therapeutics Ltd Pyrazoloý1,5-a¨pyrimidine compounds and pharmaceutical compositions containing them
AR057960A1 (es) * 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
WO2010054285A2 (en) * 2008-11-10 2010-05-14 National Health Research Institutes Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
MX2011006319A (es) 2008-12-18 2011-06-24 Bayer Cropscience Ag Amidas del acido antranilico sustituidas con tetrazol como plaguicidas.
EP2484678B1 (en) 2009-09-28 2015-01-21 Qilu Pharmaceutical Co., Ltd 4-(substituted anilino)quinazoline derivatives as tyrosine kinase inhibitors
CN102464667B (zh) * 2010-11-03 2014-06-04 中国科学院上海药物研究所 一类五元杂环并嘧啶类化合物及其制备方法和用途
CA2852964A1 (en) * 2011-11-03 2013-05-10 F. Hoffmann-La Roche Ag Bicyclic piperazine compounds
AR090037A1 (es) * 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
FR2986002B1 (fr) * 2012-01-24 2014-02-21 Servier Lab Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
MX381707B (es) 2025-03-13
SV2017005589A (es) 2018-06-01
JO3674B1 (ar) 2020-08-27
UY36734A (es) 2016-12-30
GEAP201914681A (en) 2019-09-10
PH12017502315A1 (en) 2018-06-25
US20180258098A1 (en) 2018-09-13
MA42230B1 (fr) 2020-11-30
UA122498C2 (uk) 2020-11-25
ECSP17083003A (es) 2018-02-28
RS61179B1 (sr) 2021-01-29
CL2017003205A1 (es) 2018-06-15
EP3313817A1 (en) 2018-05-02
PE20181491A1 (es) 2018-09-18
US20190248805A1 (en) 2019-08-15
CU24466B1 (es) 2020-01-03
CR20170575A (es) 2018-02-20
CA2990084C (en) 2021-04-13
DK3313817T3 (da) 2020-12-14
CA2990084A1 (en) 2016-12-29
HRP20201782T1 (hr) 2021-01-22
FR3037959B1 (fr) 2017-08-04
TW201712006A (zh) 2017-04-01
CU20170163A7 (es) 2018-05-08
GEP20207056B (en) 2020-01-10
JP2018527297A (ja) 2018-09-20
ES2831749T3 (es) 2021-06-09
KR102782071B1 (ko) 2025-03-14
EA201890126A1 (ru) 2018-06-29
CY1123645T1 (el) 2022-03-24
IL256375A (en) 2018-02-28
CN108137497A (zh) 2018-06-08
WO2016207217A1 (en) 2016-12-29
ZA201708562B (en) 2022-06-29
HUE051877T2 (hu) 2021-03-29
US10618909B2 (en) 2020-04-14
NZ738471A (en) 2024-05-31
TN2017000524A1 (en) 2019-04-12
PT3313817T (pt) 2020-11-26
RU2760554C1 (ru) 2021-11-29
PH12017502315B1 (en) 2018-06-25
JP6741699B2 (ja) 2020-08-19
AU2016282828A1 (en) 2018-01-18
SI3313817T1 (sl) 2021-01-29
PL3313817T3 (pl) 2021-04-06
MX2017016995A (es) 2018-09-07
MA42230A (fr) 2018-05-02
CN108137497B (zh) 2021-06-15
KR20180015264A (ko) 2018-02-12
GEP20197056B (en) 2020-01-10
LT3313817T (lt) 2020-11-25
EA033566B1 (ru) 2019-11-05
HK1254656A1 (zh) 2019-07-26
IL256375B (en) 2020-03-31
CO2017012832A2 (es) 2018-03-28
US10323041B2 (en) 2019-06-18
FR3037959A1 (cg-RX-API-DMAC10.html) 2016-12-30
EP3313817B1 (en) 2020-09-16
MD3313817T2 (ro) 2021-01-31
AU2016282828B2 (en) 2020-07-16

Similar Documents

Publication Publication Date Title
AR105103A1 (es) Derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen
AR105101A1 (es) Derivados aminoácido, un proceso para su preparación y composiciones farmacéuticas que los contienen
AR105104A1 (es) Derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen
AR098906A1 (es) Derivados de tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
AR108706A1 (es) Derivados piperidinilo, un proceso para su preparación, y composiciones farmacéuticas que los contienen
AR097009A1 (es) Compuestos isoindolina o isoquinolina, un proceso para su preparación, composiciones farmacéuticas que los contienen y su uso en la fabricación de un medicamento para diferentes tipos de cáncer
AR117616A1 (es) Compuestos anti-vih
AR100438A1 (es) Pirazolopiridinas y pirazolopirimidinas
AR099914A1 (es) Derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR101179A1 (es) Combinaciones anti-pd-l1 para tratar tumores
AR094550A1 (es) Inhibidores de btk
AR100886A1 (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
AR107488A1 (es) Compuestos de benzopirazol y análogos de éstos
AR103252A1 (es) Compuestos de quinazolina
AR097008A1 (es) Derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
PE20181024A1 (es) Derivados de ciclohexano sustituido con amido
AR088760A1 (es) Derivados de pirrolopirimidina y purina
AR090572A1 (es) Derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos
AR106018A1 (es) Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
AR092742A1 (es) Piridinonas antifibroticas
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR093339A1 (es) Analogos de spliceostatina y metodos para su preparacion
AR098492A1 (es) Derivados de purina
AR090293A1 (es) Inhibidores de quinasa a base de arileter
AR099874A1 (es) CROMENO Y 1,1A,2,7B-TETRAHIDROCICLOPROPA[C]CROMENO PIRIDOPIRAZINADIONAS COMO MODULADORES DE g-SECRETASA

Legal Events

Date Code Title Description
FB Suspension of granting procedure